Trial · NCT01661621
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Global Response Assessment (GRA) After the Treatment Day | Group 1 | GRA≥1 | 89 | participants | |
| The Global Response Assessment (GRA) After the Treatment Day | Group 2 | GRA≥1 | 218 | participants | |
| The Global Response Assessment (GRA) After the Treatment Day | Group 1 | GRA<1 | 27 | participants | |
| The Global Response Assessment (GRA) After the Treatment Day | Group 2 | GRA<1 | 61 | participants | |
| The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day | Group 1 | Baseline | 14.8 | Standard Deviation 5.40 | units on a scale |
| The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day | Group 2 | Baseline | 18.0 | Standard Deviation 6.47 | units on a scale |
| The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day | Group 1 | 1 month | 11.2 | Standard Deviation 6.81 | units on a scale |
| The International Prostate Symptom Score (IPSS) Questionnaires After the Treatment Day | Group 2 | 1 month | 10.8 | Standard Deviation 6.36 | units on a scale |
| The Maximum Flow Rate (Qmax) After the Treatment Day | Group 1 | Baseline | 13.1 | Standard Deviation 8.10 | mL/s |
| The Maximum Flow Rate (Qmax) After the Treatment Day | Group 2 | Baseline | 11.4 | Standard Deviation 5.95 | mL/s |
| The Maximum Flow Rate (Qmax) After the Treatment Day | Group 1 | 1 month | 13.6 | Standard Deviation 7.90 | mL/s |
| The Maximum Flow Rate (Qmax) After the Treatment Day | Group 2 | 1 month | 13.6 | Standard Deviation 6.63 | mL/s |
| The Voided Volume After the Treatment Day | Group 1 | Baseline | 212.5 | Standard Deviation 168.8 | mL |
| The Voided Volume After the Treatment Day | Group 2 | Baseline | 244.0 | Standard Deviation 148.3 | mL |
| The Voided Volume After the Treatment Day | Group 1 | 1 month | 231.6 | Standard Deviation 163.6 | mL |
| The Voided Volume After the Treatment Day | Group 2 | 1 month | 268.3 | Standard Deviation 150.7 | mL |
| The Postvoid Residual Volume (PVR) After the Treatment Day | Group 1 | Baseline | 50.1 | Standard Deviation 62.6 | mL |
| The Postvoid Residual Volume (PVR) After the Treatment Day | Group 2 | Baseline | 53.9 | Standard Deviation 58.7 | mL |
| The Postvoid Residual Volume (PVR) After the Treatment Day | Group 1 | 1 month | 60.4 | Standard Deviation 60.4 | mL |
| The Postvoid Residual Volume (PVR) After the Treatment Day | Group 2 | 1 month | 42.9 | Standard Deviation 49.3 | mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01661621/results